540 related articles for article (PubMed ID: 31931831)
1. A rapid access to addiction medicine clinic facilitates treatment of substance use disorder and reduces substance use.
Wiercigroch D; Sheikh H; Hulme J
Subst Abuse Treat Prev Policy; 2020 Jan; 15(1):4. PubMed ID: 31931831
[TBL] [Abstract][Full Text] [Related]
2. Buprenorphine/naloxone induction in a Canadian emergency department with rapid access to community-based addictions providers.
Hu T; Snider-Adler M; Nijmeh L; Pyle A
CJEM; 2019 Jul; 21(4):492-498. PubMed ID: 31006398
[TBL] [Abstract][Full Text] [Related]
3. Trends in the Use of Naltrexone for Addiction Treatment among Alcohol Use Disorder Admissions in U.S. Substance Use Treatment Facilities.
Qeadan F; Mensah NA; Gu LY; Madden EF; Venner KL; English K
Int J Environ Res Public Health; 2021 Aug; 18(16):. PubMed ID: 34444639
[TBL] [Abstract][Full Text] [Related]
4. Predictors of engagement and retention in care at a low-threshold substance use disorder bridge clinic.
Wakeman SE; McGovern S; Kehoe L; Kane MT; Powell EA; Casey SK; Yacorps GM; Irvin JR; Rodriguez W; Regan S
J Subst Abuse Treat; 2022 Oct; 141():108848. PubMed ID: 35926256
[TBL] [Abstract][Full Text] [Related]
5. COVID-19: A catalyst for change in telehealth service delivery for opioid use disorder management.
Mehtani NJ; Ristau JT; Snyder H; Surlyn C; Eveland J; Smith-Bernardin S; Knight KR
Subst Abus; 2021; 42(2):205-212. PubMed ID: 33684331
[TBL] [Abstract][Full Text] [Related]
6. Rapid Access Addiction Medicine Clinics for People With Problematic Opioid Use.
Corace K; Thavorn K; Suschinsky K; Willows M; Leece P; Kahan M; Nijmeh L; Aubin N; Roach M; Garner G; Saskin R; Kim E; Rice D; Taha S; Garber G; Hutton B
JAMA Netw Open; 2023 Nov; 6(11):e2344528. PubMed ID: 37991762
[TBL] [Abstract][Full Text] [Related]
7. Beyond Buprenorphine: Models of Follow-up Care for Opioid Use Disorder in the Emergeny Department.
Martin A; Butler K; Chavez T; Herring A; Wakeman S; Hayes BD; Raja A
West J Emerg Med; 2020 Nov; 21(6):257-263. PubMed ID: 33207174
[TBL] [Abstract][Full Text] [Related]
8. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration.
Lin LA; Bohnert ASB; Blow FC; Gordon AJ; Ignacio RV; Kim HM; Ilgen MA
Addiction; 2021 Jan; 116(1):96-104. PubMed ID: 32428386
[TBL] [Abstract][Full Text] [Related]
9. Impact of a pharmacist-led substance use disorder transitions of care clinic on postdischarge medication treatment retention.
Smith A; Hansen J; Colvard M
J Subst Abuse Treat; 2021 Nov; 130():108440. PubMed ID: 34118708
[TBL] [Abstract][Full Text] [Related]
10. Screening, treatment initiation, and referral for substance use disorders.
Bernstein SL; D'Onofrio G
Addict Sci Clin Pract; 2017 Aug; 12(1):18. PubMed ID: 28780906
[TBL] [Abstract][Full Text] [Related]
11. A hospital-wide initiative to redesign substance use disorder care: Impact on pharmacotherapy initiation.
Wakeman SE; Kane M; Powell E; Howard S; Shaw C; Kehoe L; Rosen J; Quinlan J; Regan S
Subst Abus; 2021; 42(4):767-774. PubMed ID: 33270549
[No Abstract] [Full Text] [Related]
12. Emergency department presentation of opioid use disorder and alcohol use disorder.
Xierali IM; Day PG; Kleinschmidt KC; Strenth C; Schneider FD; Kale NJ
J Subst Abuse Treat; 2021 Aug; 127():108343. PubMed ID: 34134862
[TBL] [Abstract][Full Text] [Related]
13. SAEM GRACE: Anti-craving medications for alcohol use disorder treatment in the emergency department: A systematic review of direct evidence.
Punia K; Scott W; Manuja K; Sabbineni M; Campbell K; Balodis IM; MacKillop J
Acad Emerg Med; 2024 May; 31(5):504-514. PubMed ID: 37735346
[TBL] [Abstract][Full Text] [Related]
14. Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco.
Carter J; Zevin B; Lum PJ
Addict Sci Clin Pract; 2019 May; 14(1):20. PubMed ID: 31060600
[TBL] [Abstract][Full Text] [Related]
15. Rates of substance use disorder treatment seeking visits after emergency department-initiated buprenorphine.
Jennings LK; Bogan C; McCauley JJ; Moreland A; Lane S; Ward R; Hartwell KJ; Haynes L; Brady KT
Am J Emerg Med; 2020 May; 38(5):975-978. PubMed ID: 32081555
[TBL] [Abstract][Full Text] [Related]
16. Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial.
Molfenter T; Knudsen HK; Brown R; Jacobson N; Horst J; Van Etten M; Kim JS; Haram E; Collier E; Starr S; Toy A; Madden L
Implement Sci; 2017 Nov; 12(1):135. PubMed ID: 29141653
[TBL] [Abstract][Full Text] [Related]
17. Making the business case for an addiction medicine consult service: a qualitative analysis.
Priest KC; McCarty D
BMC Health Serv Res; 2019 Nov; 19(1):822. PubMed ID: 31703741
[TBL] [Abstract][Full Text] [Related]
18. A comparison of buprenorphine and psychosocial treatment outcomes in psychosocial and medical settings.
Presnall NJ; Wolf DAPS; Brown DS; Beeler-Stinn S; Grucza RA
J Subst Abuse Treat; 2019 Sep; 104():135-143. PubMed ID: 31370977
[TBL] [Abstract][Full Text] [Related]
19. The case for a medication first approach to the treatment of opioid use disorder.
Winograd RP; Presnall N; Stringfellow E; Wood C; Horn P; Duello A; Green L; Rudder T
Am J Drug Alcohol Abuse; 2019; 45(4):333-340. PubMed ID: 31084515
[No Abstract] [Full Text] [Related]
20. Addiction Consult Service and Inpatient Outcomes Among Patients with Alcohol Use Disorder.
Singh-Tan S; Torres-Lockhart K; Jakubowski A; Lu T; Starrels J; De Lima P; Arnsten J; Nahvi S; Southern W
J Gen Intern Med; 2023 Nov; 38(14):3216-3223. PubMed ID: 37100986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
